OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants
Xiaomin Duan, Rui Shi, Pulan Liu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 13
Xiaomin Duan, Rui Shi, Pulan Liu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 13
Showing 13 citing articles:
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 67
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 67
COVID-19 and vaccination: myths vs science
Vivek P. Chavda, Yangmin Chen, Jayant Dave, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 11, pp. 1603-1620
Closed Access | Times Cited: 34
Vivek P. Chavda, Yangmin Chen, Jayant Dave, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 11, pp. 1603-1620
Closed Access | Times Cited: 34
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Molecular mechanistic exploration of conformational shifts induced by class IV anti-RBD antibody IY2A
Enhao Zhang, Song Luo, Xiaole Xu, et al.
International Journal of Biological Macromolecules (2025), pp. 141417-141417
Closed Access
Enhao Zhang, Song Luo, Xiaole Xu, et al.
International Journal of Biological Macromolecules (2025), pp. 141417-141417
Closed Access
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core
Rui Shi, Jiawei Zeng, Ling Xu, et al.
EBioMedicine (2022) Vol. 85, pp. 104297-104297
Open Access | Times Cited: 21
Rui Shi, Jiawei Zeng, Ling Xu, et al.
EBioMedicine (2022) Vol. 85, pp. 104297-104297
Open Access | Times Cited: 21
A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants
Jijing Chen, Zehong Huang, Jin Xiao, et al.
Cell Reports Methods (2024) Vol. 4, Iss. 9, pp. 100856-100856
Open Access | Times Cited: 3
Jijing Chen, Zehong Huang, Jin Xiao, et al.
Cell Reports Methods (2024) Vol. 4, Iss. 9, pp. 100856-100856
Open Access | Times Cited: 3
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 18, pp. 6497-6553
Closed Access | Times Cited: 9
Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 18, pp. 6497-6553
Closed Access | Times Cited: 9
Defining neutralization and allostery by antibodies against COVID-19 variants
Nikhil Kumar Tulsian, Raghuvamsi Venkata Palur, Xinlei Qian, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Nikhil Kumar Tulsian, Raghuvamsi Venkata Palur, Xinlei Qian, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management
Vivek P. Chavda, Aayushi Patel, Lalitkumar K. Vora, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 10, pp. 1395-1403
Closed Access | Times Cited: 13
Vivek P. Chavda, Aayushi Patel, Lalitkumar K. Vora, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 10, pp. 1395-1403
Closed Access | Times Cited: 13
A cocktail containing two synergetic antibodies broadly neutralizes SARS-CoV-2 and its variants including Omicron BA.1 and BA.2
Xinghai Zhang, Feiyang Luo, huajun Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Xinghai Zhang, Feiyang Luo, huajun Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Tengchuan Jin
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 4013-4027
Open Access | Times Cited: 6
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Tengchuan Jin
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 4013-4027
Open Access | Times Cited: 6
Defining neutralization and allostery by antibodies against COVID-19 variants
Nikhil Kumar Tulsian, Palur Venkata Raghuvamsi, Xinlei Qian, et al.
Research Square (Research Square) (2023)
Open Access
Nikhil Kumar Tulsian, Palur Venkata Raghuvamsi, Xinlei Qian, et al.
Research Square (Research Square) (2023)
Open Access
